Results 191 to 200 of about 18,081 (204)

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2018
J Flamini, Kenneth Sommerville, Renee Shellhaas   +2 more
exaly  

(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only

European Journal of Pharmacology, 2004
Raphaël Mechoulam, Lumír Hanus, Ester Fride   +2 more
exaly  

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report

Journal of Psychopharmacology, 2011
JOSÉ Crippa, Antonio Zuardi, Fabio Luis Souza-Duran   +2 more
exaly  

PROCESS FOR THE PRODUCTION OF CANNABIDIOL AND PURIFIED CANNABIDIOL

2020
DIALER LUKAS, PETROVIC DENIS, WEIGL ULRICH   +2 more
openaire   +1 more source

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

Philosophical Transactions of the Royal Society B: Biological Sciences, 2012
FRANCISCO Guimarães, Campos A C
exaly  

6ʺ-Azidohex-2ʺ-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist

European Journal of Pharmacology, 2004
Ruth Ross, Roger Pertwee, Anu Mahadevan   +2 more
exaly  

Effects of ipsapirone and cannabidiol on human experimental anxiety

Journal of Psychopharmacology, 1993
A W Zuardi, F G Graeff, F S Guimarães
exaly  

Developmental Effects of Cannabidiol and Δ9-Tetrahydrocannabinol in Zebrafish

Toxicological Sciences, 2018
Cammi Thornton, Kristine Willett, Willett Kristine L   +2 more
exaly  

Cannabidiol monotherapy for treatment-resistant schizophrenia

Journal of Psychopharmacology, 2006
JOSÉ Crippa, Antonio Zuardi, Rafael Sanches   +2 more
exaly  

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

British Journal of Pharmacology, 2007
exaly